Search Results

Risk of cardiogenic shock after thrombolysis can be predicted

Source: Reactions, Volume 1, Number 797, 2000 , pp. 3-3(1)

Publisher: Adis International

Antiplatelet Drugs Plus Thrombolysis in Myocardial Infarction: Where Are We Now?

Author: Vogt A.

Source: BioDrugs, Volume 11, Number 6, 1 June 1999 , pp. 377-383(7)

Publisher: Adis International

Recombinant Hirudin: Clinical Pharmacology and Potential Applications in Nephrology

Authors: vanholder R.; Dhondt A.

Source: BioDrugs, Volume 11, Number 6, 1 June 1999 , pp. 417-429(13)

Publisher: Adis International

Diabetic retinopathy not a contraindication for thrombolytics

Source: Reactions, Volume 1, Number 686, 1998 , pp. 5-5(1)

Publisher: Adis International

Recombinant Plasminogen Activators: A Comparative Review of the Clinical Pharmacology and Therapeutic Use of Alteplase and Reteplase

Authors: Moser M.; Kohler B.; Schmittner M.; Bode C.

Source: BioDrugs, Volume 9, Number 6, 1 June 1998 , pp. 455-463(9)

Publisher: Adis International

Thrombolysis and stroke risk in acute MI

Source: Reactions, Volume 1, Number 634, 1997 , pp. 5-5(1)

Publisher: Adis International

Efficacy of streptokinase not compromised by allergy

Source: Reactions, Volume 1, Number 652, 1997 , pp. 4-4(1)

Publisher: Adis International

Women's risk of complications with thrombolytics after MI

Source: Reactions, Volume 1, Number 595, 1996 , pp. 4-4(1)

Publisher: Adis International